Robert J Adelman
CIK 1329161 · last filed 2023-09-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
5
Total Filings
11
Lifetime Open-Market Net
-$41.03M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RayzeBio, Inc. (RYZB) Delisted | 10%+ Owner | 4,910,819 | $62.49 | $306.88M | $0 | 1 | 2023-09-21 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | 10%+ Owner | 2,155,930 | $10.50 | $22.64M | -$6.88M | 1 | 2022-05-17 |
| Metacrine, Inc. (MTCR) Delisted | Director | 2,443,421 | $0.49 | $1.21M | -$1.65M | 2 | 2021-10-26 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 3,033,552 | $54.65 | $165.78M | -$35.50M | 4 | 2020-07-06 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | 3,340,139 | — | — | $3.00M | 3 | 2008-11-18 |
Recent Filings · Page 2 of 2
11 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-11-09 | ARYx Therapeutics, Inc. (ARYX) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 11–11 of 11
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.